Genotype-guided therapy improves initial acenocoumarol dosing

Summary

A few trials so far have evaluated the effectiveness of algorithms designed to calculate doses in oral anticoagulant therapy, with negative or contradictory results. We compared a genotype-guided algorithm vs physician management for the initiation of acenocoumarol. In a twoarm, prospective, randomised study with patients with atrial fibrillation who started therapy, the first dose was administered to all patients according to the physician’s criteria. At 72 hours, the corresponding dose was calculated based on INR in the standard care group (SC, N=92), whereas genetic data (VKORC1, CYP2C9 and CYP4F2) were also considered for the genotype-guided dosing (pharmacogenetic) group (PGx, N=87) by using an algorithm previously validated in 2,683 patients. The primary outcomes were: patients with steady dose, the time needed to reach the same and the percentage of therapeutic INRs. After 90 days, 25 % of the SC and 39 % of the PGx patients reached the steady dose (p=0.038). Kaplan-Meier analysis showed that PGx group needed fewer days to reach therapeutic INR (p=0.033). Additionally, PGx had a higher percentage of therapeutic INRs than SC patients (50 % and 45 %, respectively) (p=0.046). After six months the proportion of steadily anticoagulated patients remained significantly higher in PGx (p=0.010). In conclusion, genotype-guided dosing was associated with a higher percentage of patients with steady dose than routine practice when starting oral anticoagulation with acenocoumarol.

Keywords

Acenocoumarol - algorithm - cytochromes - pharmacogenetics - vitamin K epoxide reductase complex - subunit 1 protein - human

• References

• 1 Hirsh J, Dalen JE, Anderson DR. et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114: 445S-469S.
• 2 Perez-Andreu V, Roldan V, Lopez-Fernandez MF. et al. Pharmacogenetics of acenocoumarol in patients with extreme dose requirements. J Thromb Haemost 2010; 08: 1012-1017.
• 3 Bodin L, Verstuyft C, Tregouet DA. et al. Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood 2005; 106: 135-140.
• 4 Perez-Andreu V, Roldan V, Anton AI. et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 2009; 113: 4977-4979.
• 5 Markatos CN, Grouzi E, Politou M. et al. VKORC1 and CYP2C9 allelic variants influence acenocoumarol dose requirements in Greek patients. Pharmacogenomics 2008; 09: 1631-1638.
• 6 van Schie RM, Wessels JA, le Cessie S. et al. Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 2011; 32: 1909-1917.
• 7 Borobia AM, Lubomirov R, Ramirez E. et al. An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. PLoS One 2012; 07: e41360.
• 8 Rathore SS, Agarwal SK, Pande S. et al. Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS One 2012; 07: e37844.
• 9 Cerezo-Manchado JJ, Rosafalco M, Anton AI. et al. Creating a genotype-based dosing algorithm for acenocoumarol steady dose. Thromb Haemost 2013; 109: 146-153.
• 10 Zineh I, Pacanowski M, Woodcock J. Pharmacogenetics and coumarin dosing--recalibrating expectations. N Engl J Med 2013; 369: 2273-2275.
• 11 Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists?. N Engl J Med 2013; 369: 2345-2346.
• 12 Verhoef TI, Ragia G, de Boer A. et al. A randomised trial of genotype-guided dosing of acenocoumarol and phenprocoumon. N Engl J Med 2013; 369: 2304-2312.
• 13 Pirmohamed M, Burnside G, Eriksson N. et al. A randomised trial of genotype-guided dosing of warfarin. N Engl J Med 2013; 369: 2294-2303.
• 14 Kimmel SE, French B, Kasner SE. et al. A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med 2013; 369: 2283-2293.
• 15 Li X, Yang J, Wang X. et al. Clinical benefits of pharmacogenetic algorithm-based warfarin dosing: meta-analysis of randomised controlled trials. Thromb Res 2015; 135: 621-629.
• 16 Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 03: 692-694.
• 17 Anderson JL, Horne BD, Stevens SM. et al. A randomised and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 2012; 125: 1997-2005.
• 18 Cerezo-Manchado JJ, Roldan V, Rosafalco M. et al. Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. Pharmacogenomics. 2014 ((please complete reference)).
• 19 Anton AI, Cerezo-Manchado JJ, Padilla J. et al. Novel associations of VKORC1 variants with higher acenocoumarol requirements. PLoS One 2013; 08: e64469.
• 20 Oake N, Jennings A, Forster AJ. et al. Anticoagulation intensity and outcomes among patients prescribed oral anticoagulant therapy: a systematic review and meta-analysis. CMAJ 2008; 179: 235-244.